Back to top
more

Phibro Animal Health Corporation (PAHC)

(Delayed Data from NSDQ)

$21.86 USD

21.86
322,080

-0.75 (-3.32%)

Updated Feb 24, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (159 out of 253)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

PAHC or RMD: Which Is the Better Value Stock Right Now?

PAHC vs. RMD: Which Stock Is the Better Value Option?

Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up

Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.

PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?

PAHC vs. SRDX: Which Stock Is the Better Value Option?

Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails

Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.

Why Is Phibro (PAHC) Up 1.4% Since Last Earnings Report?

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm

Lower sales of Phibro's (PAHC) Performance Products arm's copper-based products raise concerns.

Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up

Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.

PAHC vs. RMD: Which Stock Should Value Investors Buy Now?

PAHC vs. RMD: Which Stock Is the Better Value Option?

Why Is Phibro (PAHC) Down 14.8% Since Last Earnings Report?

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Phirbo's Product Mix Aids, Global Animal Health Business Ails

Phirbo (PAHC) catered industries face issues like lack of processing availability and sudden drop in demand.

Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up

Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.

Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines

Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.

Here's Why You Should Add Tandem Diabetes to Your Portfolio

Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.

Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis

Walgreens (WBA) registers growing demand for Retail Pharmacy & Pharmaceutical Wholesale products in Q2.

Abbott Launches Antibody Test to Detect Coronavirus Infection

Abbott (ABT) launches a lab-based serology blood test to detect the presence of antibodies post the coronavirus infection.

QIAGEN Launches Assay for Cancer Patients Following FDA's Nod

QIAGEN (QGEN) paves the way for metastatic CRC treatment in adults with the launch of an FDA-approved companion diagnostic test kit.

NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View

A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1

Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.

Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View

Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.

Here's Why You Should Add ResMed (RMD) in Your Portfolio

Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.

Integra Releases Preliminary Q1 Results, Withdraws '20 View

Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.

Medtronic (MDT) Demonstrates Global Growth Amid Cost Concerns

Medtronic's (MDT) international Diabetes business registers solid growth on the continued adoption of MiniMed 670G in overseas markets.

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

Investors continue to be optimistic about Thermo Fisher (TMO) on its strong segmental growth in the fourth quarter of 2019.

Product Launches Aid Hill-Rom Amid Project Timing Issues

Hill-Rom (HRC) plans to roll out five-six new products each year through 2022.